Cargando…
Common co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank
OBJECTIVE: The aim was to determine prevalent co-morbidities in cases with PMR or GCA compared with matched controls. METHODS: This was a nested, cross-sectional case–control study within the UK Biobank, which recruited participants aged 40–69 years. Case status was defined as self-reported prior di...
Autores principales: | Chatzigeorgiou, Charikleia, Taylor, John C, Elliott, Faye, O’Sullivan, Eoin P, Morgan, Ann W, Barrett, Jennifer H, Mackie, Sarah L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681851/ https://www.ncbi.nlm.nih.gov/pubmed/38033363 http://dx.doi.org/10.1093/rap/rkad095 |
Ejemplares similares
-
Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022) -
Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012) -
Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica
por: Gonzalez-Gay, Miguel A
Publicado: (2001) -
Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update
por: Nesher, Gideon, et al.
Publicado: (2016) -
Liver involvement in polymyalgia rheumatica and giant cell arteritis
por: Hysa, Elvis, et al.
Publicado: (2020)